The report gives the overview of Secondary progressive multiple sclerosis disease indication in detail, highlights the SPMS epidemiology in the key geographies, elaborates on the drugs prescribed and expected to be prescribed in SPMS and covers the detailed market sizing drug wise and country wise in value sales and patient numbers along with forecast. The report elaborates on the Secondary Progressive Multiple Sclerosis disease indication detailing the definition, causes, profile of an SPMS patient, Symptoms of SPMS patient, and disease progression in an SPMS patient.
The report further highlights the multiple methods through which the patient can be diagnosed for SPMS. The next part of the report consists of SPMS epidemiology and prevalence in the key geographies across the globe like US, UK, Germany, Italy, France, Spain, Japan etc. The epidemiology for SPMS indication across key geographies has been forecasted till 2024 as well in the report. The next part of the report highlights the importance of factors influencing the physician prescription decisions in SPMS like efficacy factors, Tolerability factors, Monitoring requirements and pricing factors.
The report further details the drugs prescribed or expected to be prescribed in SPMS by the physicians in terms of details about the formulation, molecule, mode of administration and MoA of the drugs, their patent and trial details and the expected impact of drug in the SPMS market. The report further details the drug attribute analysis drug wise on each parameter considered important in the prescription of SPMS drugs. The report also covers the other products which are currently in the pipeline for SPMS and other progressive forms of MS. The final part of the report gives a detailed overview of SPMS market sizing drug wise and geography wise both in terms of value sales and patient numbers. The drugs have been forecasted till 2030 both for value sales and patient numbers geography wise.
Price: USD 10000
*Special Offer Price: USD 5000
For Table of content Click Here
For any queries regarding the report please email at email@example.com and we would get back to you in the shortest possible time.